Phospho-GAB2 (S159) Antibody

What is Phospho-GAB2 (S159) Antibody and what does it specifically detect?

Phospho-GAB2 (S159) Antibody is a polyclonal antibody that specifically detects endogenous levels of GAB2 (GRB2-associated-binding protein 2) only when phosphorylated at serine 159. This antibody is typically raised in rabbits using a synthetic peptide derived from the region surrounding the phosphorylation site of Serine 159 in human GAB2 (with sequence context K-S-S(p)-A-P) . The antibody has demonstrated reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species .

What is the biological significance of GAB2 phosphorylation at S159?

Phosphorylation at S159 plays a critical role in negative feedback regulation of mitogenic signaling. This site is a target of protein kinase B (PKB/Akt)-mediated phosphorylation and functions as a mechanism to tightly regulate receptor-mediated signaling . When S159 is phosphorylated, GAB2 tyrosine phosphorylation is inhibited, which dampens downstream signaling events . Conversely, when this regulatory mechanism is disrupted (as in S159A mutants), enhanced and prolonged growth factor receptor signaling occurs, which can lead to cellular transformation, demonstrating the proto-oncogenic potential of GAB2 . Notably, S159 represents the only target for PKB-mediated phosphorylation on GAB2, emphasizing its specificity and importance in signal regulation .

How is GAB2 S159 phosphorylation integrated into cellular signaling networks?

S159 phosphorylation sits at the intersection of multiple signaling pathways. While initially characterized as an Akt/PKB target, recent research has revealed that S159 can also be phosphorylated by RSK (p90 ribosomal S6 kinase) downstream of the Ras/MAPK pathway . In follicle-stimulating hormone (FSH) signaling, GAB2 is phosphorylated on S159 in a PKA-dependent manner, with the sequence (RKSS160 in rat GAB2) matching the PKA consensus phosphorylation motif RR/KXSP/TP . This multi-kinase regulation highlights S159 as a key integration point for different signaling cascades that modulate GAB2 function.

What are the validated applications for Phospho-GAB2 (S159) Antibody?

Phospho-GAB2 (S159) Antibody has been validated for multiple applications, including:

• Western Blot (recommended dilution: 1/500 - 1/2000)

• Immunohistochemistry (recommended dilution: 1/100 - 1/300)

• ELISA (recommended dilution: 1/40000)

Advanced applications documented in the literature include immunoprecipitation assays to study protein complexes associated with phosphorylated GAB2, though these may require optimization depending on specific experimental conditions .

What cellular models and treatment conditions effectively induce GAB2 S159 phosphorylation?

Several experimental models have been documented for studying GAB2 S159 phosphorylation:

• HT29 cells serve as a positive control for Western blot applications detecting phosphorylated S159

• In K562 cells (a CML cell line), S159 phosphorylation persists even after treatment with tyrosine kinase inhibitors imatinib (1 μM) and dasatinib (0.01-1 μM), suggesting it is maintained through Bcr-Abl-independent mechanisms

• In HEK293 cells, phorbol myristate acetate (PMA) treatment increases S159 phosphorylation through RSK activation

• In granulosa cells, follicle-stimulating hormone (FSH) treatment induces S159 phosphorylation through PKA activation

• Growth factors like EGF and heregulin (HRG) can induce S159 phosphorylation through activation of the PI3K/Akt pathway

What methods can validate the specificity of phospho-specific GAB2 S159 detection?

To ensure specificity of Phospho-GAB2 (S159) Antibody, researchers should:

• Include appropriate positive controls (e.g., HT29 cells or cells treated with growth factors)

• Use comparative analysis with total GAB2 antibodies to normalize phospho-signal

• Employ S159A GAB2 mutants as negative controls to confirm antibody specificity

• Perform phosphatase treatment of samples to demonstrate phosphorylation-dependent recognition

• Validate with orthogonal methods, such as mass spectrometry, which has been used to identify and quantify GAB2 phosphorylation sites

How does PKB/Akt-mediated phosphorylation of GAB2 at S159 regulate signaling dynamics?

PKB/Akt phosphorylation of GAB2 at S159 creates a negative feedback loop that tightly regulates receptor-mediated signaling. Mechanistically:

• Growth factor stimulation activates the PI3K/Akt pathway

• Activated Akt phosphorylates GAB2 at S159

• This phosphorylation inhibits subsequent tyrosine phosphorylation of GAB2

• Reduced GAB2 tyrosine phosphorylation decreases association with signaling proteins like Shc and ErbB2

• Consequently, downstream signaling through ERK and PKB pathways is attenuated

This negative feedback is critical for proper signal termination. Co-expression experiments with constitutively active forms of PKB demonstrated that myr-PKBα (membrane-targeted) reduced GAB2 tyrosine phosphorylation by approximately 90%, while the T308D/S473D mutant achieved about 60% reduction .

What is the interplay between GAB2 S159 phosphorylation and other phosphorylation sites?

GAB2 undergoes complex, multi-site phosphorylation with intricate interconnections:

• S159 phosphorylation works in concert with other regulatory phosphorylation sites, including S210 and T391, which serve as 14-3-3 protein binding sites

• Mass spectrometry studies have identified at least 19 novel serine/threonine phosphorylation sites on GAB2, revealing a complex "phosphomap"

• In a study examining GAB2 mutations, a 4×A mutant (S159A, S210A, T391A, and S668A) showed enhanced tyrosine phosphorylation compared to wild-type GAB2, with S159A contributing significantly to this enhancement

• While S159 is exclusively phosphorylated by Akt in vitro, S210 and T391 phosphorylation appears to be regulated by both PI3K/Akt and other pathways

This complex network of phosphorylation events highlights the sophisticated regulation of GAB2 function in signal transduction.

How does RSK-mediated phosphorylation of GAB2 S159 differ from Akt-mediated phosphorylation?

Both RSK and Akt can phosphorylate GAB2 at S159, but with distinct regulatory consequences:

• RSK phosphorylates GAB2 at S159 as part of a trio of sites (S160/S211/S620 in mouse GAB2, corresponding to S159/S210/S619 in human) in response to Ras/MAPK pathway activation

• RSK-mediated phosphorylation specifically inhibits Shp2 recruitment to GAB2 following growth factor stimulation, whereas Akt-mediated phosphorylation appears to more broadly inhibit GAB2 tyrosine phosphorylation

• Mutation of RSK target sites (S160/211/620A) enhances Shp2 recruitment to GAB2 and potentiates ERK1/2 phosphorylation in response to EGF stimulation

• The inhibitory effects of RSK on Shp2 recruitment appear to be specific, as no modulation was observed in the recruitment of p85 (PI3K regulatory subunit) in response to EGF stimulation

These differences highlight how similar phosphorylation events can have context-dependent signaling outcomes depending on the upstream kinase.

How can researchers distinguish between Akt, RSK, and PKA-mediated phosphorylation of GAB2 S159?

To differentiate between kinase contributions to S159 phosphorylation:

• Use specific kinase inhibitors:

  • For Akt: Employ Akt inhibitors (Akt-I-1/2) and PI3K inhibitors (wortmannin)

  • For RSK: Use RSK inhibitor BI-D1870 and MEK inhibitors (PD184352, UO126)

  • For PKA: Apply PKA inhibitors or disruptors of PKA anchoring (e.g., RIAD peptide)

• Monitor pathway activity markers simultaneously:

  • Measure phosphorylation of known Akt substrates (e.g., GSK3β)

  • Assess ERK1/2 phosphorylation as an indicator of MAPK pathway activation

  • Evaluate CREB phosphorylation as a readout of PKA activity

• Perform time-course experiments:

  • In FSH signaling, GAB2(S159) phosphorylation precedes AKT(Ser473) phosphorylation

  • In EGF signaling, kinetic differences may exist between Akt and RSK activation

• Use immunoprecipitation with phospho-specific antibodies:

  • Anti-p-PKA substrate antibody that recognizes RXXSP/TP motifs can selectively immunoprecipitate PKA-phosphorylated GAB2

What are the technical challenges in studying GAB2 S159 phosphorylation dynamics?

Researchers face several challenges when investigating GAB2 S159 phosphorylation:

• Overlapping kinase specificities: S159 can be phosphorylated by multiple kinases (Akt, RSK, PKA), making it difficult to isolate specific pathways

• Background phosphorylation: Some experimental systems show constitutive phosphorylation of S159, S210, and T391, even after treatment with kinase inhibitors

• Context-dependent regulation: The contribution of different pathways to S159 phosphorylation varies by cell type (e.g., ERK/RSK plays a minor role in K562 cells compared to HEK293 cells)

• Interaction with other phosphorylation events: Changes in S159 phosphorylation should be interpreted in the context of the complete GAB2 "phosphomap"

• Detection sensitivity: Subtle changes in phosphorylation may require quantitative methods like SILAC-based mass spectrometry rather than antibody-based detection

How can functional consequences of GAB2 S159 phosphorylation be experimentally assessed?

To evaluate the functional impact of S159 phosphorylation:

• Compare wild-type GAB2 with S159A mutants in:

  • Tyrosine phosphorylation assays following growth factor stimulation

  • Co-immunoprecipitation studies to assess protein-protein interactions

  • Downstream signaling activation (ERK, Akt pathways)

  • Biological assays (proliferation, transformation, migration)

• Assess cellular transformation:

  • S159A GAB2 mutants induce spindle-shaped, refractile morphology in NIH 3T3 cells

  • Measure anchorage-independent growth through soft agar colony formation assays

  • Compare with known oncogenes (e.g., active src and transforming neu) as positive controls

• Examine the dynamics of signaling complex formation:

  • Investigate recruitment of signaling proteins (Shp2, p85, 14-3-3)

  • Study the temporal regulation of complex assembly/disassembly

  • Assess the impact on receptor tyrosine phosphorylation and stability

What factors influence successful detection of phospho-GAB2 (S159) in Western blots?

For optimal Western blot results:

• Sample preparation:

  • Use phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Lyse cells in appropriate buffer (e.g., PBS with 50% glycerol and 0.02% sodium azide, pH 7.4)

  • Consider specialized lysis conditions for membrane-associated protein complexes

• Antibody conditions:

  • Optimize antibody dilution (recommended range: 1/500 - 1/2000)

  • Use proper blocking agents to reduce background

  • Consider longer incubation times at 4°C

• Controls and normalization:

  • Include positive controls (e.g., HT29 cells)

  • Analyze total GAB2 levels in parallel for normalization

  • Consider using S159A GAB2 mutants as negative controls

• Signal detection:

  • Monitor electrophoretic mobility shifts as indirect indicators of phosphorylation status

  • Be aware that other phosphorylation events can influence GAB2 mobility on SDS-PAGE

How can researchers interpret complex phosphorylation patterns of GAB2 across different experimental conditions?

Interpreting complex GAB2 phosphorylation patterns requires:

• Comprehensive analysis approach:

  • Compare phospho-specific antibody results with total protein electrophoretic mobility

  • Use mass spectrometry to identify and quantify multiple phosphorylation sites simultaneously

  • Apply SILAC-based quantification for relative abundance comparison

• Consider signaling context:

  • Evaluate pathway inhibitors' effects on S159 phosphorylation (e.g., IM and DST have minimal impact)

  • Recognize that S159 phosphorylation may persist even when ERK phosphorylation is inhibited

  • Assess correlation between S159 phosphorylation and 14-3-3 protein binding

• Apply quantitative analysis:

  • Use a 2-fold change threshold (common in phosphoproteomics) to discriminate responding from non-responding sites

  • Compare relative changes across multiple experiments to identify consistent patterns

  • Consider kinetic differences in phosphorylation/dephosphorylation events

What alternative approaches can validate findings from phospho-GAB2 (S159) antibody-based studies?

To validate antibody-based findings:

• Genetic approaches:

  • Express phospho-mimetic (S159D/E) or phospho-deficient (S159A) GAB2 mutants

  • Use CRISPR/Cas9 to generate endogenous S159A mutations

  • Apply siRNA/shRNA to knockdown specific kinases

• Pharmacological validation:

  • Use multiple structurally distinct kinase inhibitors

  • Combine inhibitors targeting different pathway components

  • Apply dose-response studies to correlate inhibitor potency with S159 phosphorylation

• Mass spectrometry:

  • Perform quantitative phosphoproteomic analysis

  • Use targeted mass spectrometry to focus on specific phosphopeptides

  • Apply SILAC or TMT labeling for comparative analysis

• Functional readouts:

  • Correlate S159 phosphorylation with downstream biological effects

  • Use reporter gene assays to measure pathway activation

  • Assess changes in protein-protein interactions through proximity ligation assays